Clinical Trial Update: A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated whether a genetic test panel can predict response to golimumab in adults with moderately to severely active ulcerative colitis; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Golimumab (golimumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Colitis, Ulcerative | Phase 2 | Status: COMPLETED